Harald Jüppner mostly deals with Internal medicine, Endocrinology, Parathyroid hormone, Receptor and Fibroblast growth factor 23. His studies deal with areas such as Cancer research and Peptide as well as Internal medicine. His study in Hypophosphatemia, Autosomal dominant hypophosphatemic rickets, Hyperparathyroidism, Kidney and PHEX falls within the category of Endocrinology.
His biological study spans a wide range of topics, including Calcitriol, Calcium metabolism and Mutation. His work on Peptide hormone as part of general Receptor study is frequently linked to Parathyroid hormone receptor, bridging the gap between disciplines. His work carried out in the field of Fibroblast growth factor 23 brings together such families of science as Osteomalacia, Osteoid and Phosphate.
His main research concerns Internal medicine, Endocrinology, Parathyroid hormone, Receptor and Parathyroid hormone receptor. His study in Fibroblast growth factor 23, Pseudohypoparathyroidism, Kidney disease, Kidney and Calcium are all subfields of Internal medicine. The concepts of his Fibroblast growth factor 23 study are interwoven with issues in Vitamin D and neurology, Osteomalacia, Hypophosphatemia and Phosphate.
His Endocrinology research is multidisciplinary, incorporating elements of Calcium metabolism, Secondary hyperparathyroidism and GNAS complex locus. His Parathyroid hormone study incorporates themes from Calcitriol, Renal osteodystrophy, Bone remodeling and Peptide sequence. His research integrates issues of Molecular biology, Signal transduction and Peptide in his study of Receptor.
His primary areas of investigation include Internal medicine, Endocrinology, Pseudohypoparathyroidism, GNAS complex locus and Fibroblast growth factor 23. Parathyroid hormone, Kidney disease, Kidney, Vitamin D and neurology and Nephrology are subfields of Internal medicine in which his conducts study. His work is dedicated to discovering how Parathyroid hormone, Receptor are connected with In vivo and other disciplines.
His research in the fields of Nephrocalcinosis overlaps with other disciplines such as Context. Harald Jüppner interconnects Pseudopseudohypoparathyroidism, Epigenetics, Allele and Exon in the investigation of issues within GNAS complex locus. His Fibroblast growth factor 23 study also includes fields such as
Harald Jüppner mainly investigates Internal medicine, Endocrinology, Fibroblast growth factor 23, Kidney disease and Vitamin D and neurology. His study in Internal medicine is interdisciplinary in nature, drawing from both Osteocyte, MEDLINE and Cardiology. His work deals with themes such as Parathyroid hormone and Pseudohypoparathyroidism, which intersect with Endocrinology.
Harald Jüppner works mostly in the field of Parathyroid hormone, limiting it down to topics relating to Receptor and, in certain cases, Homeostasis. His Fibroblast growth factor 23 research is multidisciplinary, incorporating perspectives in Hypophosphatemia, Osteomalacia, Klotho and Effector, Cell biology. He interconnects Interquartile range, Renal function, Secondary hyperparathyroidism, Confidence interval and Risk factor in the investigation of issues within Kidney disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Primer on the metabolic bone diseases and disorders of mineral metabolism
John P. Bilezikian;Roger Bouillon;Thomas Clemens;Juliet Compston.
Rhode Island dental journal (2013)
LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
Y. Q. Gong;R. B. Slee;N. Fukai;G. Rawadi.
A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide
Harald Jüppner;Abdul Badi Abou-Samra;Mason Freeman;Xiang F. Kong.
A novel cyclin encoded by a bcl1 -linked candidate oncogene
Toru Motokura;Theodora Bloom;Hyung Goo Kim;Harald Jüppner..
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.
Orlando M. Gutiérrez;Michael Mannstadt;Tamara Isakova;Jose Alejandro Rauh-Hain.
The New England Journal of Medicine (2008)
PTH/PTHrP Receptor in Early Development and Indian Hedgehog--Regulated Bone Growth
Beate Lanske;Andrew C. Karaplis;Kaechong Lee;Arne Luz.
Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease
Orlando Gutierrez;Tamara Isakova;Eugene Rhee;Anand Shah.
Journal of The American Society of Nephrology (2005)
Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium
A B Abou-Samra;H Jüppner;T Force;M W Freeman.
Proceedings of the National Academy of Sciences of the United States of America (1992)
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
Tobias Larsson;U.L.F. Nisbeth;Östen Ljunggren;Harald Jüppner.
Kidney International (2003)
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Kenneth B Jonsson;Richard Zahradnik;Tobias Larsson;Kenneth E White.
The New England Journal of Medicine (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: